T1	SectionAnnotate 275 301	History of Present Illness
T2	SectionSkip 1083 3029	Pathology showed a pT2N2, 3.3 cm poorly differentiated adenocarcinoma, LVI present, PNI negative, 11/37 lymph nodes, negative margins, MMR intact.     Postoperative CT scan (08/02/19) showed a new soft tissue area inferior to the pancreas, c/w either postoperative changes or recurrent/residual disease. She then started back on chemotherapy with FOLFIRINOX on 08/07/19 and completed 11 cycles in total, through 01/09/20.     She underwent incisional hernia repair in June 2020, after which time she noted persistent mid-back pain. Surveillance CT C/A/P (09/10/20) showed enlarging aortocaval and gastrohepatic lymph nodes, new subcentimeter mesenteric lymph nodes, and ongoing hazy attenuation/stranding encasing the peripancreatic vasculature. EUS-guided sampling of an 18 mm lymph node in the gastrohepatic ligament region confirmed metastatic adenocarcinoma 
 (09/12/20).    She started on the combination of gemcitabine and nab-paclitaxel with an every other week dosing schedule beginning on 09/19/20. Recent restaging CT (10/24/20) after approximately 6 weeks on treatment showed mildly decreased size of intra-abdominal lymph nodes which have become less defined. No new intra-abdominal or intrathoracic disease. New subtle groundglass opacities throughout the lungs in the upper lobes may be related to an infectious/inflammatory etiology.     The patient's present review of systems was reviewed. She denies any pain at present (currently on once-daily long-acting morphine), and reports tolerating current chemotherapy very well, aside from mild fatigue and transient nausea. Appetite is good and weight is stable/improving. She has minimal non-debilitating peripheral sensory neuropathy. Bowel movements are regular and well-formed. She continues to be very active, with an ECOG PS of 0.      PAST MEDICAL AND SURGICAL HISTORY  Hypertension  Hyperlipidemia  Adenomatous polyp (2011)  History of cryptogenic organizing pneumonia (2013)
T3	SectionSkip 3033 3069	ALLERGIES: Erythromycin causing rash
T4	SectionSkip 3073 3822	MEDICATIONS:    acetaminophen (TYLENOL PO) take by mouth every day    amylase-lipase-protease (Creon 24,000) 120,000-24,000-76,000 delayed release capsule take 2 Caps by mouth 3 times a day with meals (Patient taking differently: take 2 Caps by mouth 2 times a day ) 270 Cap 3    cholecalciferol (vitamin D3) (VITAMIN D3 PO) take 5,000 Int'l Units by mouth every day    morphine (MS Contin) 15 mg controlled release tablet take 1 Tablet (15 mg total) by mouth daily 30 Tablet 0    polyethylene glycol (MIRAlax) 17 gram packet take 17 g by mouth One Time    potassium chloride (Klor-Con) 20 mEq sustained release tablet take 2 Tabs (40 mEq total) by mouth 2 times a day (Patient taking differently: take 20 mEq by mouth every morning ) 60 Tab 2
T5	SectionAnnotate 3826 3853	PERSONAL AND SOCIAL HISTORY
T6	SectionAnnotate 4025 4039	FAMILY HISTORY
T7	SectionSkip 4437 5479	Physical Exam:  Blood pressure 126/65, pulse 52, temperature 36.9 C (98.4 F), temperature source Temporal, resp. rate 16, height 164 cm (5' 4.57"), weight 70 kg (154 lb 4.8 oz), SpO2 98 %. ECOG PS 0.  General appearance: No acute distress, conversant, appropriately interactive. Non-toxic, well-appearing.   Eyes: anicteric sclerae, moist conjunctivae; no lid lag.   HEENT: Atraumatic; oropharynx clear with moist mucous membranes and no mucosal ulcerations; normal hard and soft palate  Neck: Full range of motion, supple, no lymphadenopathy  Lungs/respiratory: Clear to auscultation, with normal respiratory effort and no intercostal retractions  Cardiovascular: RRR, normal S1 S2, no murmurs, gallops, or rubs.  Abdomen/GI: Soft, non-tender, nondistended; no masses, ascites, or hepatomegaly. Tympanitic to percussion.  Back: No point spinal tenderness.  Extremities: No peripheral edema or discoloration palpated or visualized.  Skin: Normal temperature, turgor and texture; no rash, ulcers or subcutaneous nodules visualized or palpated.
T8	SectionSkip 5650 9781	RELEVANT DIAGNOSTIC STUDIES    Most recent labs notable for the following:   11/21/20  WBC 5, Hb 10.7, plt 137  Cr 0.67  ALT 70, AST 66, ALP 522  Total bili 0.5, alb 4    CA 19-9 
 levels  11/21/20=61  10/24/20=133  10/10/20=433  09/19/20=746        FNA 09/12/20  CYTOLOGIC DIAGNOSIS:   lymph node, gastrohepatic, endoscopic us-guided fine needle   aspiration        --   metastatic adenocarcinoma (see comment)     COMMENT:  The aspirate smear and cell block contain a malignant   population of cells with increased nuclear size, increased nuclear   to cytoplasmic ratio, and irregular nuclear contours. The malignant   cells are arranged in loosely cohesive clusters within a background   of lymphoid tissue. Collectively, the features are diagnostic of   metastatic adenocarcinoma. Suggest clinical and radiologic   correlation.    Whipple resection 07/09/19  DIAGNOSIS (MICROSCOPIC):   A. PANCREAS, NECK MARGIN, BIOPSY (FSA)   --   NEGATIVE FOR CARCINOMA (SEE COMMENT)   B. PANCREAS, BILE DUCT MARGIN, BIOPSY (FSB)   --   NEGATIVE FOR CARCINOMA   C. PANCREAS, SMA MARGIN, BIOPSY (FSC)   --   NEGATIVE FOR CARCINOMA   D. LYMPH NODE, ADJACENT TO D4, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   E. LYMPH NODE, HEPATIC ARTERY, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   F. LYMPH NODE, CALOT, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   G. PANCREAS, REMAINDER OF CYSTIC DUCT, BIOPSY   --   NEGATIVE FOR CARCINOMA   H. PANCREAS AND DUODENUM AND GALLBLADDER, PANCREATICODUODENECTOMY   AND CHOLECYSTECTOMY        PANCREAS AND DUODENUM   --   INVASIVE, MODERATELY TO POORLY-DIFFERENTIATED ADENOCARCINOMA   3.3 CM, EXCISED (SEE COMMENT AND SUMMARY TABLE)   --   METASTATIC ADENOCARCINOMA IN ELEVEN OF THIRTY FOUR LYMPH NODES   (11/34)        GALLBLADDER             --   NO SIGNIFICANT ABNORMALITY     COMMENT:  Histologic sections of the Whipple specimen (part H)   demonstrate the adenocarcinoma is located 0.1 cm from the vascular   groove.  Multiple lymph nodes are positive for metastatic carcinoma   (April 34) and there is extensive lymphovascular invasion and small   vein invasion.  We 
 have reviewed the frozen section slides and   concur with the intraoperative diagnoses. Immunohistochemistry for   mismatch repair proteins is being performed on block ***** with   results to be reported in an addendum.  Additional prognostic   details are provided in the summary table below.     PANCREAS (EXOCRINE)   SPECIMEN   Procedure:     Pancreaticoduodenectomy (Whipple resection), partial   pancreatectomy   TUMOR   Tumor Site:    Specified   Pancreatic head   .   Histologic Type:    Ductal adenocarcinoma   Histologic Grade:   G3: Poorly differentiated   Tumor Size:    3.3cm   Tumor Extent   Tumor Extension:    Evidence of primary tumor   Can be assessed   Tumor invades duodenal wall   Accessory Findings   Treatment Effect:   Cannot be determined   No tumor regression however only one cycle of neoadjuvant   chemotherapy is given.   Lymphovascular Invasion: Present   Perineural Invasion:     Not identified   MARGINS   All margins are uninvolved by invasive carcinoma and high-grade   intraepithelial neoplasia   Margins Examined:   Pancreatic neck / parenchymal   Uncinate (retroperitoneal / superior mesenteric artery)   Bile duct   Proximal (gastric or duodenal)   Distal (duodenal or jejunal)   Distance of Invasive Carcinoma from Closest Margin:    0.7cm   Closest Margin:     Uncinate (retroperitoneal / superior mesenteric   artery)   LYMPH NODES   Regional Lymph Nodes:    Lymph nodes submitted or found   Number of Lymph Nodes Involved:    11   Number of Lymph Nodes Examined:    37   PATHOLOGIC STAGE CLASSIFICATION  (pTNM, AJCC 8th Edition)   TNM Descriptors:    Not applicable   .   Primary Tumor (pT): pT2   Regional Lymph Nodes (pN):    pN2   Distant Metastasis (pM):   Not applicable - pM cannot be determined from the submitted   specimen(s)    MMR proteins all intact by IHC.      I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology 
 reports, as follows:    CT C/A/P 10/24/20
T9	SectionSkip 9783 12150	FINDINGS:     CHEST:   Medical devices: Right-sided port with tip in the cavoatrial junction     Thyroid: Normal.       Lymph nodes: No supraclavicular, axillary, mediastinal, or hilar lymphadenopathy.     Vasculature: Aorta and main pulmonary artery diameters are within normal range.     Heart: Mild coronary artery calcification. No pericardial effusion.     Other mediastinal structures: Normal.     Lung parenchyma and pleura: No new or enlarging nodules. Unchanged 3 mm nodule in the apical right upper lobe (January 70). Subtle areas of groundglass throughout both lungs (8/80, 96, 106). No pleural effusions.     Airways: Normal.     Chest wall: Normal.     ABDOMEN/PELVIS:   Liver and biliary tree: Unchanged hypoattenuating lesion in segment IVb measuring 0.7 cm (7/83) which may represent a hemangioma (MR 05/30/2019). No new or enlarging lesions. Mild intrahepatic duct dilation with left-sided pneumobilia, unchanged. Mild periportal edema.     Gallbladder: Surgically absent.     Spleen: Enlarged measuring up to 13.3 cm.     Pancreas: Status post Whipple's. Remaining parenchyma is atrophic, unchanged. No focal lesions.     No sign of any change of hazy stranding surrounding the pancreas with greater than 180 degrees involvement of the celiac axis and common hepatic artery, gastroduodenal artery as well as the main portal and splenic veins..     Adrenal glands: Unchanged left adrenal adenoma and thickening. Right adrenal is normal.     Kidneys and ureters: Normal.     Gastrointestinal tract: Post Whipple changes. Anastomosis appears intact. No evidence of obstruction. Diverticulosis without evidence of diverticulitis. Appendix is normal.     Peritoneal cavity: No free air or fluid. Similar mesenteric edema.     Bladder: Normal.     Uterus: Normal.     Ovaries: Normal.     Vasculature: Atherosclerosis without aneurysm.     Lymph nodes: Several lymph nodes have mildly decreased in 
 size and overall appear less defined. For reference:   -Portacaval node measuring 2.4 x 1.2 cm (December 94) is unchanged   -Gastrohepatic measuring 1.8 x 1.2 cm (December 76) (previously 2.0 x 1.5 cm)   -Aortocaval measuring 1.5 x 0.7 cm (December 236) (previously 2.2 x 1.6 cm)     No new enlarged nodes.     Abdominal wall: Post surgical changes in the ventral wall..     Musculoskeletal: Degenerative change of the spine. No aggressive osseous lesions
T11	SectionAnnotate 12649 12680	Impression and Recommendations:
T12	PROBLEM 128 178	her recurrent metastatic pancreatic adenocarcinoma
T13	PROBLEM 328 357	a known germline ATM mutation
T14	PROBLEM 399 435	resectable pancreatic adenocarcinoma
T15	PROBLEM 458 475	painless jaundice
T16	TEST 477 479	CT
T17	PROBLEM 514 549	a 2x2.7x2.9 cm pancreatic head mass
T18	PROBLEM 555 613	associated pancreatic ductal and biliary ductal dilatation
T19	TEST 615 618	EUS
T20	TEST 626 629	FNA
T21	ClinicalCondition 661 686	pancreatic adenocarcinoma
T22	TEST 702 715	several ERCPs
T23	TREATMENT 720 743	biliary stent placement
T24	TREATMENT 782 810	a percutaneous biliary drain
T25	PROBLEM 853 875	her hyperbilirubinemia
T26	TREATMENT 905 924	FOLFOX chemotherapy
T27	TREATMENT 943 953	irinotecan
T28	PROBLEM 969 987	elevated bilirubin
T29	TREATMENT 1021 1040	a Whipple resection
T30	TEST 1083 1092	Pathology
T31	TEST 1100 1107	a pT2N2
T32	PROBLEM 1109 1152	3.3 cm poorly differentiated adenocarcinoma
T33	TEST 1154 1157	LVI
T34	TEST 1167 1170	PNI
T35	TEST 1234 1255	Postoperative CT scan
T36	PROBLEM 1274 1296	a new soft tissue area
T37	PROBLEM 1334 1355	postoperative changes
T38	PROBLEM 1359 1385	recurrent/residual disease
T39	TREATMENT 1412 1424	chemotherapy
T40	TREATMENT 1430 1440	FOLFIRINOX
T41	TREATMENT 1523 1547	incisional hernia repair
T42	PROBLEM 1589 1613	persistent mid-back pain
T43	TEST 1615 1636	Surveillance CT C/A/P
T44	PROBLEM 1655 1705	enlarging aortocaval and gastrohepatic lymph nodes
T45	PROBLEM 1707 1747	new subcentimeter mesenteric lymph nodes
T46	PROBLEM 1753 1827	ongoing hazy attenuation/stranding encasing the peripancreatic vasculature
T47	TEST 1829 1832	EUS
T48	TEST 1833 1848	guided sampling
T49	TREATMENT 1852 1871	an 18 mm lymph node
T50	PROBLEM 1919 1944	metastatic adenocarcinoma
T51	TREATMENT 1996 2007	gemcitabine
T52	TREATMENT 2012 2026	nab-paclitaxel
T53	TEST 2091 2110	Recent restaging CT
T54	TREATMENT 2153 2162	treatment
T55	PROBLEM 2170 2222	mildly decreased size of intra-abdominal lymph nodes
T56	PROBLEM 2258 2302	new intra-abdominal or intrathoracic disease
T57	PROBLEM 2304 2376	New subtle groundglass opacities throughout the lungs in the upper lobes
T58	PROBLEM 2395 2430	an infectious/inflammatory etiology
T59	PROBLEM 2501 2509	any pain
T60	TREATMENT 2535 2566	once-daily long-acting morphine
T61	TREATMENT 2592 2612	current chemotherapy
T62	PROBLEM 2635 2647	mild fatigue
T63	PROBLEM 2652 2668	transient nausea
T64	TEST 2691 2697	weight
T65	PROBLEM 2727 2781	minimal non-debilitating peripheral sensory neuropathy
T66	PROBLEM 2848 2859	very active
T67	TEST 2866 2876	an ECOG PS
T68	PROBLEM 2923 2951	Hypertension  Hyperlipidemia
T69	PROBLEM 2953 2970	Adenomatous polyp
T70	PROBLEM 2990 3022	cryptogenic organizing pneumonia
T71	TREATMENT 3044 3056	Erythromycin
T72	PROBLEM 3065 3069	rash
T73	TREATMENT 3090 3116	acetaminophen (TYLENOL PO)
T74	TREATMENT 3145 3175	amylase-lipase-protease (Creon
T75	TREATMENT 3356 3400	cholecalciferol (vitamin D3) (VITAMIN D3 PO)
T76	TREATMENT 3447 3467	morphine (MS Contin)
T77	TREATMENT 3559 3588	polyethylene glycol (MIRAlax)
T78	TREATMENT 3636 3665	potassium chloride (Klor-Con)
T79	PROBLEM 3898 3913	prostate cancer
T80	PROBLEM 4068 4085	esophageal cancer
T81	PROBLEM 4107 4115	melanoma
T82	ClinicalCondition 4138 4151	breast cancer
T83	PROBLEM 4207 4218	brain tumor
T84	PROBLEM 4302 4316	uveal melanoma
T85	PROBLEM 4352 4366	ovarian cancer
T86	TEST 4453 4467	Blood pressure
T87	TEST 4476 4481	pulse
T88	TEST 4486 4497	temperature
T89	TEST 4503 4504	C
T90	TEST 4515 4533	temperature source
T91	TEST 4550 4554	rate
T92	TEST 4559 4565	height
T93	TEST 4585 4591	weight
T94	TEST 4615 4619	SpO2
T95	TEST 4626 4633	ECOG PS
T96	PROBLEM 4661 4675	acute distress
T97	PROBLEM 4751 4768	anicteric sclerae
T98	PROBLEM 4793 4800	lid lag
T99	PROBLEM 4811 4821	Atraumatic
T100	PROBLEM 4875 4894	mucosal ulcerations
T101	PROBLEM 4964 4979	lymphadenopathy
T102	TEST 5009 5021	auscultation
T103	PROBLEM 5061 5084	intercostal retractions
T104	PROBLEM 5124 5131	murmurs
T105	PROBLEM 5133 5140	gallops
T106	PROBLEM 5145 5149	rubs
T107	PROBLEM 5170 5180	non-tender
T108	PROBLEM 5182 5194	nondistended
T109	PROBLEM 5199 5205	masses
T110	PROBLEM 5207 5214	ascites
T111	PROBLEM 5219 5231	hepatomegaly
T112	TEST 5247 5257	percussion
T113	PROBLEM 5269 5292	point spinal tenderness
T114	PROBLEM 5311 5327	peripheral edema
T115	PROBLEM 5331 5344	discoloration
T116	PROBLEM 5419 5423	rash
T117	PROBLEM 5425 5431	ulcers
T118	PROBLEM 5435 5455	subcutaneous nodules
T119	PROBLEM 5568 5595	focal sensorimotor deficits
T120	TEST 5681 5697	Most recent labs
T121	TEST 5737 5740	WBC
T122	TEST 5744 5746	Hb
T123	TEST 5753 5756	plt
T124	TEST 5762 5764	Cr
T125	TEST 5771 5774	ALT
T126	TEST 5779 5782	AST
T127	TEST 5787 5790	ALP
T128	TEST 5796 5806	Total bili
T129	TEST 5812 5815	alb
T130	TEST 5821 5823	CA
T131	TEST 5831 5837	levels
T132	TEST 5900 5903	FNA
T133	PROBLEM 5937 5947	lymph node
T134	PROBLEM 5949 6009	gastrohepatic, endoscopic us-guided fine needle   aspiration
T135	PROBLEM 6022 6047	metastatic adenocarcinoma
T136	TEST 6076 6094	The aspirate smear
T137	TEST 6099 6109	cell block
T138	PROBLEM 6118 6151	a malignant   population of cells
T139	PROBLEM 6157 6179	increased nuclear size
T140	PROBLEM 6181 6221	increased nuclear   to cytoplasmic ratio
T141	PROBLEM 6227 6253	irregular nuclear contours
T142	PROBLEM 6255 6276	The malignant   cells
T143	PROBLEM 6344 6359	lymphoid tissue
T144	PROBLEM 6408 6433	metastatic adenocarcinoma
T145	TEST 6443 6480	clinical and radiologic   correlation
T146	TREATMENT 6485 6502	Whipple resection
T147	TEST 6540 6578	A. PANCREAS, NECK MARGIN, BIOPSY (FSA)
T148	PROBLEM 6599 6608	CARCINOMA
T149	TEST 6656 6668	BIOPSY (FSB)
T150	TEST 6726 6738	BIOPSY (FSC)
T151	PROBLEM 6759 6784	CARCINOMA   D. LYMPH NODE
T152	TEST 6802 6808	BIOPSY
T153	TEST 6816 6830	ONE LYMPH NODE
T154	PROBLEM 6844 6853	CARCINOMA
T155	TEST 6893 6899	BIOPSY
T156	TEST 6907 6921	ONE LYMPH NODE
T157	PROBLEM 6935 6944	CARCINOMA
T158	TEST 6975 6981	BIOPSY
T159	TEST 6989 7003	ONE LYMPH NODE
T160	PROBLEM 7017 7026	CARCINOMA
T161	TEST 7074 7080	BIOPSY
T162	PROBLEM 7101 7153	CARCINOMA   H. PANCREAS AND DUODENUM AND GALLBLADDER
T163	TREATMENT 7155 7178	PANCREATICODUODENECTOMY
T164	TREATMENT 7185 7200	CHOLECYSTECTOMY
T165	PROBLEM 7237 7297	INVASIVE, MODERATELY TO POORLY-DIFFERENTIATED ADENOCARCINOMA
T166	PROBLEM 7355 7380	METASTATIC ADENOCARCINOMA
T167	TEST 7394 7417	THIRTY FOUR LYMPH NODES
T168	PROBLEM 7467 7490	SIGNIFICANT ABNORMALITY
T169	TEST 7528 7548	the Whipple specimen
T170	PROBLEM 7572 7590	the adenocarcinoma
T171	PROBLEM 7638 7658	Multiple lymph nodes
T172	PROBLEM 7676 7696	metastatic carcinoma
T173	PROBLEM 7723 7756	extensive lymphovascular invasion
T174	PROBLEM 7761 7782	small   vein invasion
T175	TEST 7804 7829	the frozen section slides
T176	TEST 7878 7898	Immunohistochemistry
T177	TREATMENT 7905 7929	mismatch repair proteins
T178	TREATMENT 8136 8178	Pancreaticoduodenectomy (Whipple resection
T179	TREATMENT 8181 8213	partial   pancreatectomy   TUMOR
T180	PROBLEM 8285 8306	Ductal adenocarcinoma
T181	PROBLEM 8333 8367	Poorly differentiated   Tumor Size
T182	PROBLEM 8380 8410	Tumor Extent   Tumor Extension
T183	PROBLEM 8427 8440	primary tumor
T184	PROBLEM 8558 8574	tumor regression
T185	TREATMENT 8601 8627	neoadjuvant   chemotherapy
T186	PROBLEM 8640 8663	Lymphovascular Invasion
T187	PROBLEM 8757 8775	invasive carcinoma
T188	PROBLEM 8780 8818	high-grade   intraepithelial neoplasia
T189	PROBLEM 8841 9037	Pancreatic neck / parenchymal   Uncinate (retroperitoneal / superior mesenteric artery)   Bile duct   Proximal (gastric or duodenal)   Distal (duodenal or jejunal)   Distance of Invasive Carcinoma
T190	TEST 9189 9200	Lymph nodes
T191	TEST 9403 9421	Primary Tumor (pT)
T192	PROBLEM 9459 9483	pN2   Distant Metastasis
T193	PROBLEM 9569 9581	MMR proteins
T194	TEST 9644 9682	the patient's relevant imaging studies
T195	TEST 9764 9772	CT C/A/P
T196	TREATMENT 9806 9821	Medical devices
T197	TREATMENT 9823 9839	Right-sided port
T198	PROBLEM 9919 9983	supraclavicular, axillary, mediastinal, or hilar lymphadenopathy
T199	PROBLEM 10080 10114	Mild coronary artery calcification
T200	PROBLEM 10119 10139	pericardial effusion
T201	PROBLEM 10218 10242	new or enlarging nodules
T202	PROBLEM 10244 10296	Unchanged 3 mm nodule in the apical right upper lobe
T203	PROBLEM 10327 10360	groundglass throughout both lungs
T204	PROBLEM 10381 10398	pleural effusions
T205	PROBLEM 10491 10538	Unchanged hypoattenuating lesion in segment IVb
T206	PROBLEM 10583 10595	a hemangioma
T207	TEST 10597 10599	MR
T208	PROBLEM 10616 10640	new or enlarging lesions
T209	PROBLEM 10642 10673	Mild intrahepatic duct dilation
T210	PROBLEM 10679 10701	left-sided pneumobilia
T211	PROBLEM 10714 10735	Mild periportal edema
T212	TREATMENT 10845 10854	Whipple's
T213	PROBLEM 10880 10888	atrophic
T214	PROBLEM 10904 10917	focal lesions
T215	PROBLEM 10948 10987	hazy stranding surrounding the pancreas
T216	PROBLEM 11165 11195	Unchanged left adrenal adenoma
T217	PROBLEM 11200 11210	thickening
T218	PROBLEM 11298 11318	Post Whipple changes
T219	TREATMENT 11320 11331	Anastomosis
T220	PROBLEM 11363 11374	obstruction
T221	PROBLEM 11376 11390	Diverticulosis
T222	PROBLEM 11411 11425	diverticulitis
T223	TEST 11451 11468	Peritoneal cavity
T224	PROBLEM 11473 11481	free air
T225	PROBLEM 11485 11490	fluid
T226	PROBLEM 11492 11516	Similar mesenteric edema
T227	PROBLEM 11597 11612	Atherosclerosis
T228	PROBLEM 11621 11629	aneurysm
T229	PROBLEM 11648 11667	Several lymph nodes
T230	PROBLEM 11673 11699	mildly decreased in 
 size
T231	TEST 11751 11766	Portacaval node
T232	PROBLEM 11982 12000	new enlarged nodes
T233	PROBLEM 12022 12063	Post surgical changes in the ventral wall
T234	PROBLEM 12087 12119	Degenerative change of the spine
T235	PROBLEM 12124 12150	aggressive osseous lesions
T236	PROBLEM 12172 12192	Postsurgical changes
T237	TREATMENT 12198 12207	Whipple's
T238	PROBLEM 12212 12258	significant change of peripancreatic stranding
T239	PROBLEM 12294 12346	Mildly decreased size of intra-abdominal lymph nodes
T240	PROBLEM 12417 12444	new intra-abdominal disease
T241	PROBLEM 12468 12489	intrathoracic disease
T242	PROBLEM 12491 12544	New subtle groundglass opacities throughout the lungs
T243	PROBLEM 12592 12615	infectious/inflammatory
T244	PROBLEM 12619 12642	drug related etiologies
T245	PROBLEM 12729 12758	a known germline ATM mutation
T246	PROBLEM 12763 12809	recurrent metastatic pancreatic adenocarcinoma
T247	PROBLEM 12856 12874	resectable disease
T248	TREATMENT 12899 12905	FOLFOX
T249	TREATMENT 12915 12932	Whipple resection
T250	PROBLEM 12949 12962	pT2N2 disease
T251	PROBLEM 12970 12981	lymph nodes
T252	TREATMENT 13009 13028	adjuvant FOLFIRINOX
T253	PROBLEM 13089 13130	biopsy-proven mesenteric nodal recurrence
T254	TREATMENT 13179 13190	gemcitabine
T255	TREATMENT 13191 13205	nab-paclitaxel
T256	TEST 13395 13404	pathology
T257	TEST 13406 13420	investigations
T258	TREATMENT 13426 13435	treatment
T259	TREATMENT 13469 13478	treatment
T260	TREATMENT 13497 13513	systemic therapy
T261	TREATMENT 13656 13665	treatment
T262	TREATMENT 13785 13792	therapy
T263	TREATMENT 13861 13874	her treatment
T264	TREATMENT 13919 13930	gemcitabine
T265	TREATMENT 13931 13945	nab-paclitaxel
T266	PROBLEM 14045 14086	maximal radiographic/biochemical response
T267	TREATMENT 14148 14170	a chemotherapy holiday
T268	TREATMENT 14212 14231	radiation treatment
T269	PROBLEM 14243 14263	any residual disease
T270	TREATMENT 14312 14331	palliative purposes
T271	PROBLEM 14344 14364	isolated recurrences
T272	TREATMENT 14439 14458	prolonging survival
T273	TREATMENT 14475 14491	future treatment
T274	PROBLEM 14522 14533	her disease
T275	TREATMENT 14576 14592	SoC chemotherapy
T276	TREATMENT 14618 14650	LV plus nanoliposomal irinotecan
T277	TREATMENT 14652 14659	nal-IRI
T278	TREATMENT 14664 14671	Onivyde
T279	TEST 14972 14979	A study
T280	TREATMENT 14990 15004	nab-paclitaxel
T281	TREATMENT 15009 15060	a glucocorticoid receptor antagonist (relacorilant)
T282	TREATMENT 15071 15098	a pancreas-specific cohort)
T283	TEST 15108 15115	A study
T284	TREATMENT 15119 15132	pembrolizumab
T285	TREATMENT 15134 15145	lenvantinib
T286	TREATMENT 15151 15168	a HIF2a inhibitor
T287	TREATMENT 15249 15272	disease-agnostic trials
T288	TREATMENT 15338 15355	a RAD51 inhibitor
T289	TREATMENT 15394 15410	an ATR inhibitor
T290	PROBLEM 15429 15442	ATM mutations
T291	PROBLEM 15505 15520	pancreas cancer
T292	TEST 15551 15572	a FoundationOne panel
T293	TEST 15596 15621	somatic tumor 
 profiling
T294	PROBLEM 15716 15736	actionable mutations
T295	PROBLEM 16144 16161	Her active cancer
T296	PROBLEM 16173 16199	a life-threatening illness
T297	PROBLEM 16210 16223	complications
T298	TREATMENT 16248 16266	patient management
T299	TREATMENT 16274 16311	the patient's systemic cancer therapy
T300	TEST 16333 16353	intensive monitoring
T301	PROBLEM 16358 16401	potential major/life-threatening toxicities
T302	Age 15 17	69
T303	GenomicTestResult 345 357	ATM mutation
A1	NegationModalityVal T303 affirmed
A2	GenomicTestType T303 Germline
T304	Datetime 385 393	May 2019
T305	ClinicalCondition 410 435	pancreatic adenocarcinoma
A3	ContinuityVal T305 unclear
T306	Symptom 458 475	painless jaundice
A4	IsPresentOnFirstCancerDiagnosis T306 yes
A5	IsCausedByDiagnosedCancer T306 yes
A6	ChronicVal T306 non-chronic
A7	ContinuityVal T306 unclear
T307	ProcedureName 477 483	CT A/P
A8	IntentVal T307 diagnosis
T308	ProcedureName 615 618	EUS
A9	IntentVal T308 diagnosis
T309	ProcedureName 626 629	FNA
A10	IntentVal T309 diagnosis
T310	ProcedureName 710 714	ERCP
A11	IntentVal T310 others
T311	ProcedureName 784 810	percutaneous biliary drain
A12	IntentVal T311 others
T312	ProcedureName 728 756	stent placement and exchange
A13	IntentVal T312 others
A14	TreatmentTypeVal T310 others
A15	TreatmentCategory T310 Others
A16	TreatmentTypeVal T312 others
A17	TreatmentCategory T312 Others
A18	TreatmentTypeVal T311 others
A19	TreatmentCategory T311 Others
T313	ClinicalCondition 857 875	hyperbilirubinemia
A20	ChronicVal T313 non-chronic
A21	ContinuityVal T313 stopped
R1	TestOrProcedureConductedForProblem Test:T311 Prob:T313	
R2	TestOrProcedureConductedForProblem Test:T312 Prob:T313	
R3	TestOrProcedureConductedForProblem Test:T310 Prob:T313	
T314	Datetime 631 639	05/18/19
A22	ChronicVal T21 non-chronic
A23	ContinuityVal T21 new
R4	HappensAtOnDuring Arg1:T314 Arg2:T309	
R5	HappensAtOnDuring Arg1:T314 Arg2:T308	
R6	TestOrProcedureReveals Test:T308 Desc:T21	
R7	TestOrProcedureReveals Test:T309 Desc:T21	
T315	Datetime 497 505	05/16/19
R8	HappensAtOnDuring Arg1:T315 Arg2:T307	
T316	Size 516 528	2x2.7x2.9 cm
A24	HistoryVal T316 new
A25	EpisodeDescription T316 FirstOccurrence
R9	TestOrProcedureReveals Test:T307 Desc:T316	
T317	RadPathResult 566 613	pancreatic ductal and biliary ductal dilatation
A26	RadPathResultVal T317 Others
R10	ResultOfTest Desc:T317 Test:T307	
R11	BeginsOnOrAt Arg1:T304 Arg2:T305	
R12	BeginsOnOrAt Arg1:T304 Arg2:T306	
T318	Datetime 812 820	06/05/19
R13	HappensBefore Arg1:T312 Arg2:T318	
R14	HappensAtOnDuring Arg1:T311 Arg2:T318	
R15	HappensBefore Arg1:T310 Arg2:T318	
T319	Cycles 894 895	1
T320	MedicationRegimen 905 911;912 924	FOLFOX chemotherapy
A27	TreatmentContinuityVal T320 finished
A28	TreatmentTypeVal T320 neoadjuvant
A29	TreatmentIntentVal T320 curative
R16	TreatmentDesc Therapy:T319 Desc:T320	
T321	Datetime 928 936	06/15/19
R17	HappensAtOnDuring Arg1:T320 Arg2:T321	
T322	MedicationName 943 953	irinotecan
A30	NegationModalityVal T322 negated
T323	LabTestResult 969 987	elevated bilirubin
A31	LabTestResultVal T323 abnormal
R18	ExclusionCriteriaFor Arg1:T323 Arg2:T322	
T324	ProcedureName 1023 1040	Whipple resection
A32	IntentVal T324 treatment-curative
A33	TreatmentTypeVal T324 local
A34	TreatmentCategory T324 AntiNeoPlastics
A35	IsTumorRemaining T324 no
T325	Datetime 1073 1081	07/09/19
R19	HappensAtOnDuring Arg1:T325 Arg2:T324	
T326	TNM 1102 1107	pT2N2
A36	EpisodeDescription T326 FirstOccurrence
T327	Size 1109 1115	3.3 cm
A37	EpisodeDescription T327 FirstOccurrence
T328	Histology 1138 1152	adenocarcinoma
A38	EpisodeDescription T328 FirstOccurrence
T329	Grade 1116 1137	poorly differentiated
A39	EpisodeDescription T329 FirstOccurrence
T330	LocalInvasion 1154 1157	LVI
A40	EpisodeDescription T330 FirstOccurrence
T331	LocalInvasion 1167 1170	PNI
A41	NegationModalityVal T331 negated
T332	LymphNodeInvolvement 1181 1186	11/37
A42	EpisodeDescription T332 FirstOccurrence
T333	MarginStatus 1209 1216	margins
A43	MarginVal T333 MoreThan2mm(Neg)
R20	ProcedureDesc Procedure:T333 Desc:T324	
T334	DiagnosticLabTest 1218 1221	MMR
A44	IntentVal T334 diagnosis
T335	LabTestResult 1222 1228	intact
A45	RadPathResultVal T335 InitialCancerDiagnosis
A46	LabTestResultVal T335 normal
R21	ResultOfTest Desc:T335 Test:T334	
T336	Radiology 1248 1255	CT scan
A47	IntentVal T336 TreatmentAssessment
T337	Datetime 1257 1265	08/02/19
R22	HappensAtOnDuring Arg1:T337 Arg2:T336	
T338	RadPathResult 1276 1296	new soft tissue area
A48	RadPathResultVal T338 Unclear
R23	ResultOfTest Desc:T338 Test:T336	
T339	Site 1313 1321	pancreas
R24	SiteOf Arg1:T339 Arg2:T338	
T340	TreatmentType 1412 1424	chemotherapy
A49	TreatmentContinuityVal T340 started
A50	TreatmentTypeVal T340 adjuvant
A51	TreatmentIntentVal T340 curative
T341	TreatmentType 1430 1440	FOLFIRINOX
A52	TreatmentContinuityVal T341 started
A53	TreatmentTypeVal T341 adjuvant
A54	TreatmentIntentVal T341 curative
T342	Datetime 1444 1452	08/07/19
R25	BeginsOnOrAt Arg1:T342 Arg2:T341	
R26	BeginsOnOrAt Arg1:T342 Arg2:T340	
T343	Cycles 1467 1469	11
R27	TreatmentDesc Therapy:T343 Desc:T341	
T344	Datetime 1495 1503	01/09/20
R28	EndsOnOrAt Arg1:T344 Arg2:T341	
T345	ProcedureName 1523 1547	incisional hernia repair
A55	TreatmentTypeVal T345 others
A56	TreatmentCategory T345 Others
T346	Datetime 1551 1560	June 2020
R29	HappensAtOnDuring Arg1:T346 Arg2:T345	
T347	Symptom 1609 1613	pain
A57	IsPresentOnFirstCancerDiagnosis T347 no
A58	IsCausedByDiagnosedCancer T347 no
A59	ChronicVal T347 non-chronic
A60	ContinuityVal T347 new
T348	Site 1600 1608	mid-back
R30	SiteOf Arg1:T348 Arg2:T347	
R31	BeginsOnOrAt Arg1:T347 Arg2:T346	
R32	ConditionOrTreatmentCausesProblem Treatment:T345 Prob:T347	
T349	Datetime 1638 1646	09/10/20
T350	Radiology 1628 1636	CT C/A/P
A61	IntentVal T350 TreatmentAssessment
R33	HappensAtOnDuring Arg1:T350 Arg2:T349	
T351	RadPathResult 1655 1705	enlarging aortocaval and gastrohepatic lymph nodes
A62	RadPathResultVal T351 Progression
T352	RadPathResult 1707 1747	new subcentimeter mesenteric lymph nodes
A63	RadPathResultVal T352 Progression
T353	RadPathResult 1761 1787	hazy attenuation/stranding
A64	RadPathResultVal T353 Unclear
T354	Site 1801 1827	peripancreatic vasculature
R34	SiteOf Arg1:T354 Arg2:T353	
R35	ResultOfTest Desc:T351 Test:T350	
R36	ResultOfTest Desc:T352 Test:T350	
R37	ResultOfTest Desc:T353 Test:T350	
T355	ProcedureName 1829 1848	EUS-guided sampling
A65	IntentVal T355 diagnosis
A66	IsTumorRemaining T355 yes
T356	Size 1855 1860	18 mm
A67	EpisodeDescription T356 Progression
T357	Site 1861 1871	lymph node
R38	SiteOf Arg1:T357 Arg2:T356	
R39	SiteOf Arg1:T357 Arg2:T355	
T358	Site 1879 1901	gastrohepatic ligament
R40	SiteOf Arg1:T358 Arg2:T356	
T359	Histology 1930 1944	adenocarcinoma
A68	EpisodeDescription T359 Progression
T360	Metastasis 1919 1929	metastatic
A69	EpisodeDescription T360 Progression
R41	TestOrProcedureReveals Test:T355 Desc:T360	
R42	TestOrProcedureReveals Test:T355 Desc:T359	
T361	MedicationRegimen 1996 2026	gemcitabine and nab-paclitaxel
A70	TreatmentContinuityVal T361 started
A71	TreatmentTypeVal T361 maintenance
A72	TreatmentIntentVal T361 palliative
T362	Frequency 2035 2051	every other week
R43	Temporal Arg1:T362 Arg2:T361	
T363	Datetime 2081 2089	09/19/20
R44	BeginsOnOrAt Arg1:T363 Arg2:T361	
T364	Datetime 2112 2120	10/24/20
T365	Radiology 2098 2110	restaging CT
A73	IntentVal T365 TreatmentAssessment
R45	HappensAtOnDuring Arg1:T364 Arg2:T365	
T366	Duration 2142 2149	6 weeks
T367	RadPathResult 2170 2191	mildly decreased size
A75	RadPathResultVal T367 TreatmentResponse
R46	ResultOfTest Desc:T367 Test:T365	
T368	Site 2195 2222	intra-abdominal lymph nodes
R47	SiteOf Arg1:T368 Arg2:T367	
T369	RadPathResult 2258 2302	new intra-abdominal or intrathoracic disease
A76	RadPathResultVal T369 Progression
R48	ResultOfTest Desc:T369 Test:T365	
T370	RadPathResult 2308 2336	subtle groundglass opacities
A77	NegationModalityVal T370 affirmed
A78	RadPathResultVal T370 Others
A79	NegationModalityVal T369 negated
T371	Site 2352 2376	lungs in the upper lobes
R49	SiteOf Arg1:T371 Arg2:T370	
T372	Symptom 2505 2509	pain
A80	NegationModalityVal T372 negated
T373	Symptom 2670 2678	Appetite
A81	NegationModalityVal T373 negated
T374	Symptom 2635 2647	mild fatigue
A82	IsCausedByDiagnosedCancer T374 no
A83	ChronicVal T374 non-chronic
A84	ContinuityVal T374 unclear
T375	Symptom 2652 2668	transient nausea
A85	IsCausedByDiagnosedCancer T375 no
A86	ChronicVal T375 non-chronic
A87	ContinuityVal T375 unclear
T376	TreatmentType 2600 2612	chemotherapy
A88	TreatmentContinuityVal T376 continuing
A89	TreatmentTypeVal T376 maintenance
A90	TreatmentIntentVal T376 palliative
R50	ConditionOrTreatmentCausesProblem Treatment:T376 Prob:T374	
R51	ConditionOrTreatmentCausesProblem Treatment:T376 Prob:T375	
T377	Symptom 2752 2782	peripheral sensory neuropathy.
A91	IsPresentOnFirstCancerDiagnosis T377 no
A92	ChronicVal T377 non-chronic
A93	ContinuityVal T377 unclear
T378	ClinicalCondition 4352 4366	ovarian cancer
A94	NegationModalityVal T378 affirmed
A95	ChronicVal T378 chronic
A96	ExperiencerVal T378 family
T379	ClinicalCondition 4302 4316	uveal melanoma
A97	NegationModalityVal T379 affirmed
A98	ChronicVal T379 chronic
A99	ExperiencerVal T379 family
T380	ClinicalCondition 4068 4085	esophageal cancer
A100	NegationModalityVal T380 affirmed
A101	ChronicVal T380 chronic
A102	ExperiencerVal T380 family
T381	ClinicalCondition 4107 4115	melanoma
A103	NegationModalityVal T381 affirmed
A104	ChronicVal T381 chronic
A105	ExperiencerVal T381 family
A106	NegationModalityVal T82 affirmed
A107	ChronicVal T82 chronic
A108	ExperiencerVal T82 family
T382	Age 4017 4019	49
T383	Age 4133 4136	40s
T384	Age 4326 4329	63y
T385	Age 4397 4400	78y
T386	Age 4169 4172	70s
T387	Age 4182 4185	78y
T388	ClinicalCondition 4207 4218	brain tumor
A109	NegationModalityVal T388 affirmed
A110	ChronicVal T388 chronic
A111	ExperiencerVal T388 family
T389	Age 4384 4387	70s
T390	Duration 4225 4236	four months
T391	ClinicalCondition 2923 2935	Hypertension
A113	ChronicVal T391 chronic
A114	ContinuityVal T391 stable
T392	ClinicalCondition 2937 2951	Hyperlipidemia
A115	ChronicVal T392 chronic
A116	ContinuityVal T392 stable
T393	ClinicalCondition 2953 2970	Adenomatous polyp
A117	ChronicVal T393 chronic
A118	ContinuityVal T393 stable
T394	ClinicalCondition 2990 3022	cryptogenic organizing pneumonia
A119	ChronicVal T394 chronic
A120	ContinuityVal T394 stopped
T395	Datetime 2972 2976	2011
R52	HappensAtOnDuring Arg1:T395 Arg2:T393	
T396	Datetime 3024 3028	2013
R53	HappensAtOnDuring Arg1:T396 Arg2:T394	
T397	MaritalStatus 3855 3862	Married
A121	NegationModalityVal T397 affirmed
A122	IsStoppedOrContinuing T397 continuing
A123	ExperiencerVal T397 patient
T398	Tobacco 3958 3973	Previous smoker
A124	NegationModalityVal T398 affirmed
A125	IsStoppedOrContinuing T398 stopped
T399	ConsumptionQuantity 3975 3992;3993 4003	10 cigarettes/day x 30 years
T400	SectionSkip 12154 12642	IMPRESSION:   1.  Postsurgical changes from Whipple's. No significant change of peripancreatic stranding, for attention on follow-up.   2.  Mildly decreased size of intra-abdominal lymph nodes which have become less defined which may be posttreatment related. No new intra-abdominal disease.   3.   No evidence of intrathoracic disease. New subtle groundglass opacities throughout the lungs particularly in the upper lobes may related to infectious/inflammatory or drug related etiologies
A126	SectionSkipType T400 radiology_report
T401	Age 12709 12711	69
T402	GenomicTestResult 12746 12758	ATM mutation
A127	GenomicTestType T402 Germline
T403	ClinicalCondition 12784 12809	pancreatic adenocarcinoma
A128	ChronicVal T403 chronic
A129	ContinuityVal T403 stable
T404	Metastasis 12773 12783	metastatic
A130	EpisodeDescription T404 Progression
T405	Datetime 12842 12850	May 2019
T406	LocalInvasion 12856 12874	resectable disease
A131	NegationModalityVal T406 negated
A132	EpisodeDescription T406 FirstOccurrence
T407	Cycles 12888 12889	1
T408	MedicationRegimen 12899 12905	FOLFOX
A133	TreatmentContinuityVal T408 finished
A134	TreatmentTypeVal T408 neoadjuvant
A135	TreatmentIntentVal T408 curative
R54	TreatmentDesc Therapy:T407 Desc:T408	
T409	ProcedureName 12915 12932	Whipple resection
A136	IntentVal T409 treatment-curative
A137	TreatmentTypeVal T409 local
A138	TreatmentCategory T409 AntiNeoPlastics
A139	IsTumorRemaining T409 unclear
T410	Datetime 12934 12942	07/09/19
R55	HappensAtOnDuring Arg1:T410 Arg2:T409	
T411	TNM 12949 12954	pT2N2
A140	EpisodeDescription T411 FirstOccurrence
T412	LymphNodeInvolvement 12964 12969	11/37
A141	EpisodeDescription T412 FirstOccurrence
T413	Cycles 12996 12998	11
T414	MedicationRegimen 13018 13028	FOLFIRINOX
A142	TreatmentContinuityVal T414 finished
A143	TreatmentTypeVal T414 adjuvant
A144	TreatmentIntentVal T414 curative
T415	Datetime 13043 13051	01/09/20
R56	TreatmentDesc Therapy:T413 Desc:T414	
R57	EndsOnOrAt Arg1:T415 Arg2:T414	
T416	Metastasis 13103 13130	mesenteric nodal recurrence
A145	EpisodeDescription T416 Progression
T417	Datetime 13134 13142	09/12/20
R58	HappensAtOnDuring Arg1:T417 Arg2:T416	
T418	Cycles 13167 13168	3
T419	MedicationRegimen 13179 13205	gemcitabine/nab-paclitaxel
A146	TreatmentContinuityVal T419 continuing
A147	TreatmentTypeVal T419 maintenance
A148	TreatmentIntentVal T419 palliative
R59	TreatmentDesc Therapy:T418 Desc:T419	
T420	MedicationRegimen 13919 13945	gemcitabine/nab-paclitaxel
A149	TreatmentTypeVal T420 maintenance
A150	TreatmentIntentVal T420 palliative
T421	Frequency 13954 13970	every other week
R60	Temporal Arg1:T421 Arg2:T420	
T422	Cycles 14099 14100	6
R61	TreatmentDesc Therapy:T420 Desc:T422	
T423	TreatmentType 14212 14231	radiation treatment
A151	NegationModalityVal T423 hypothetical_in_future
A152	TreatmentTypeVal T423 local
A153	TreatmentIntentVal T423 palliative
T424	TreatmentType 14576 14592	SoC chemotherapy
A154	NegationModalityVal T424 hypothetical_in_future
A155	TreatmentIntentVal T424 palliative
T425	MedicationRegimen 14613 14672	5-FU/LV plus nanoliposomal irinotecan (nal-IRI, or Onivyde)
A156	NegationModalityVal T425 hypothetical_in_future
A157	TreatmentIntentVal T425 palliative
T426	ClinicalTrial 14990 15060	nab-paclitaxel and a glucocorticoid receptor antagonist (relacorilant)
A158	NegationModalityVal T426 hypothetical_in_future
T427	ClinicalTrial 15119 15168	pembrolizumab, lenvantinib, and a HIF2a inhibitor
A159	NegationModalityVal T427 hypothetical_in_future
T428	ClinicalTrial 15338 15355	a RAD51 inhibitor
A160	NegationModalityVal T428 hypothetical_in_future
T429	ClinicalTrial 15385 15410	trial of an ATR inhibitor
A161	NegationModalityVal T429 hypothetical_in_future
T430	GenomicTest 15553 15572	FoundationOne panel
A162	NegationModalityVal T430 planned_in_future
A163	ExperiencerVal T430 patient
A164	IntentVal T430 diagnosis
A165	GenomicTestType T430 Somatic
T431	GenomicTestResult 15716 15736	actionable mutations
A166	GenomicTestType T431 Somatic
R62	ResultOfTest Desc:T431 Test:T430	
T432	SectionSkip 4437 5643	Physical Exam:  Blood pressure 126/65, pulse 52, temperature 36.9 C (98.4 F), temperature source Temporal, resp. rate 16, height 164 cm (5' 4.57"), weight 70 kg (154 lb 4.8 oz), SpO2 98 %. ECOG PS 0.  General appearance: No acute distress, conversant, appropriately interactive. Non-toxic, well-appearing.   Eyes: anicteric sclerae, moist conjunctivae; no lid lag.   HEENT: Atraumatic; oropharynx clear with moist mucous membranes and no mucosal ulcerations; normal hard and soft palate  Neck: Full range of motion, supple, no lymphadenopathy  Lungs/respiratory: Clear to auscultation, with normal respiratory effort and no intercostal retractions  Cardiovascular: RRR, normal S1 S2, no murmurs, gallops, or rubs.  Abdomen/GI: Soft, non-tender, nondistended; no masses, ascites, or hepatomegaly. Tympanitic to percussion.  Back: No point spinal tenderness.  Extremities: No peripheral edema or discoloration palpated or visualized.  Skin: Normal temperature, turgor and texture; no rash, ulcers or subcutaneous nodules visualized or palpated.  Neuro: Normal bulk, tone, and strength in upper and lower extremities. Intact gait. No focal sensorimotor deficits.  Psych: Appropriate affect, alert and oriented
A167	SectionSkipType T432 physical_exam
T433	SectionSkip 5650 5828;5831 5892	RELEVANT DIAGNOSTIC STUDIES    Most recent labs notable for the following:   11/21/20  WBC 5, Hb 10.7, plt 137  Cr 0.67  ALT 70, AST 66, ALP 522  Total bili 0.5, alb 4    CA 19-9 levels  11/21/20=61  10/24/20=133  10/10/20=433  09/19/20=746
A168	SectionSkipType T433 laboratory
T434	SectionSkip 5900 7787;7790 9600	FNA 09/12/20  CYTOLOGIC DIAGNOSIS:   lymph node, gastrohepatic, endoscopic us-guided fine needle   aspiration        --   metastatic adenocarcinoma (see comment)     COMMENT:  The aspirate smear and cell block contain a malignant   population of cells with increased nuclear size, increased nuclear   to cytoplasmic ratio, and irregular nuclear contours. The malignant   cells are arranged in loosely cohesive clusters within a background   of lymphoid tissue. Collectively, the features are diagnostic of   metastatic adenocarcinoma. Suggest clinical and radiologic   correlation.    Whipple resection 07/09/19  DIAGNOSIS (MICROSCOPIC):   A. PANCREAS, NECK MARGIN, BIOPSY (FSA)   --   NEGATIVE FOR CARCINOMA (SEE COMMENT)   B. PANCREAS, BILE DUCT MARGIN, BIOPSY (FSB)   --   NEGATIVE FOR CARCINOMA   C. PANCREAS, SMA MARGIN, BIOPSY (FSC)   --   NEGATIVE FOR CARCINOMA   D. LYMPH NODE, ADJACENT TO D4, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   E. LYMPH NODE, HEPATIC ARTERY, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   F. LYMPH NODE, CALOT, BIOPSY   --   ONE LYMPH NODE NEGATIVE FOR CARCINOMA (0/1)   G. PANCREAS, REMAINDER OF CYSTIC DUCT, BIOPSY   --   NEGATIVE FOR CARCINOMA   H. PANCREAS AND DUODENUM AND GALLBLADDER, PANCREATICODUODENECTOMY   AND CHOLECYSTECTOMY        PANCREAS AND DUODENUM   --   INVASIVE, MODERATELY TO POORLY-DIFFERENTIATED ADENOCARCINOMA   3.3 CM, EXCISED (SEE COMMENT AND SUMMARY TABLE)   --   METASTATIC ADENOCARCINOMA IN ELEVEN OF THIRTY FOUR LYMPH NODES   (11/34)        GALLBLADDER             --   NO SIGNIFICANT ABNORMALITY     COMMENT:  Histologic sections of the Whipple specimen (part H)   demonstrate the adenocarcinoma is located 0.1 cm from the vascular   groove.  Multiple lymph nodes are positive for metastatic carcinoma   (April 34) and there is extensive lymphovascular invasion and small   vein invasion.  We have reviewed the frozen section slides and   concur with the intraoperative diagnoses. Immunohistochemistry for   mismatch repair proteins is being performed on block ***** with   results to be reported in an addendum.  Additional prognostic   details are provided in the summary table below.     PANCREAS (EXOCRINE)   SPECIMEN   Procedure:     Pancreaticoduodenectomy (Whipple resection), partial   pancreatectomy   TUMOR   Tumor Site:    Specified   Pancreatic head   .   Histologic Type:    Ductal adenocarcinoma   Histologic Grade:   G3: Poorly differentiated   Tumor Size:    3.3cm   Tumor Extent   Tumor Extension:    Evidence of primary tumor   Can be assessed   Tumor invades duodenal wall   Accessory Findings   Treatment Effect:   Cannot be determined   No tumor regression however only one cycle of neoadjuvant   chemotherapy is given.   Lymphovascular Invasion: Present   Perineural Invasion:     Not identified   MARGINS   All margins are uninvolved by invasive carcinoma and high-grade   intraepithelial neoplasia   Margins Examined:   Pancreatic neck / parenchymal   Uncinate (retroperitoneal / superior mesenteric artery)   Bile duct   Proximal (gastric or duodenal)   Distal (duodenal or jejunal)   Distance of Invasive Carcinoma from Closest Margin:    0.7cm   Closest Margin:     Uncinate (retroperitoneal / superior mesenteric   artery)   LYMPH NODES   Regional Lymph Nodes:    Lymph nodes submitted or found   Number of Lymph Nodes Involved:    11   Number of Lymph Nodes Examined:    37   PATHOLOGIC STAGE CLASSIFICATION  (pTNM, AJCC 8th Edition)   TNM Descriptors:    Not applicable   .   Primary Tumor (pT): pT2   Regional Lymph Nodes (pN):    pN2   Distant Metastasis (pM):   Not applicable - pM cannot be determined from the submitted   specimen(s)    MMR proteins all intact by IHC.
A169	SectionSkipType T434 pathology_report
T435	SectionSkip 9606 9737;9740 11692;11695 12150	I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:    CT C/A/P 10/24/20  FINDINGS:     CHEST:   Medical devices: Right-sided port with tip in the cavoatrial junction     Thyroid: Normal.       Lymph nodes: No supraclavicular, axillary, mediastinal, or hilar lymphadenopathy.     Vasculature: Aorta and main pulmonary artery diameters are within normal range.     Heart: Mild coronary artery calcification. No pericardial effusion.     Other mediastinal structures: Normal.     Lung parenchyma and pleura: No new or enlarging nodules. Unchanged 3 mm nodule in the apical right upper lobe (January 70). Subtle areas of groundglass throughout both lungs (8/80, 96, 106). No pleural effusions.     Airways: Normal.     Chest wall: Normal.     ABDOMEN/PELVIS:   Liver and biliary tree: Unchanged hypoattenuating lesion in segment IVb measuring 0.7 cm (7/83) which may represent a hemangioma (MR 05/30/2019). No new or enlarging lesions. Mild intrahepatic duct dilation with left-sided pneumobilia, unchanged. Mild periportal edema.     Gallbladder: Surgically absent.     Spleen: Enlarged measuring up to 13.3 cm.     Pancreas: Status post Whipple's. Remaining parenchyma is atrophic, unchanged. No focal lesions.     No sign of any change of hazy stranding surrounding the pancreas with greater than 180 degrees involvement of the celiac axis and common hepatic artery, gastroduodenal artery as well as the main portal and splenic veins..     Adrenal glands: Unchanged left adrenal adenoma and thickening. Right adrenal is normal.     Kidneys and ureters: Normal.     Gastrointestinal tract: Post Whipple changes. Anastomosis appears intact. No evidence of obstruction. Diverticulosis without evidence of diverticulitis. Appendix is normal.     Peritoneal cavity: No free air or fluid. Similar mesenteric edema.     Bladder: Normal.     Uterus: Normal.     Ovaries: Normal.     Vasculature: Atherosclerosis without aneurysm.     Lymph nodes: Several lymph nodes have mildly decreased in size and overall appear less defined. For reference:   -Portacaval node measuring 2.4 x 1.2 cm (December 94) is unchanged   -Gastrohepatic measuring 1.8 x 1.2 cm (December 76) (previously 2.0 x 1.5 cm)   -Aortocaval measuring 1.5 x 0.7 cm (December 236) (previously 2.2 x 1.6 cm)     No new enlarged nodes.     Abdominal wall: Post surgical changes in the ventral wall..     Musculoskeletal: Degenerative change of the spine. No aggressive osseous lesions
A170	SectionSkipType T435 radiology_report
R64	EndsOnOrAt Arg1:T398 Arg2:T382	
R65	ConsumptionQuantityRel Arg1:T398 Arg2:T399	
R66	BeginsOnOrAt Arg1:T381 Arg2:T383	
R67	BeginsOnOrAt Arg1:T82 Arg2:T386	
R68	EndsOnOrAt Arg1:T82 Arg2:T387	
R69	EndsOnOrAt Arg1:T388 Arg2:T390	
R70	EndsOnOrAt Arg1:T379 Arg2:T384	
R71	BeginsOnOrAt Arg1:T378 Arg2:T389	
R72	EndsOnOrAt Arg1:T378 Arg2:T385	
T436	PatientCharacteristics 4414 4429	Jewish ancestry
A171	NegationModalityVal T436 negated
T10	DiseaseState 12763 12772	recurrent
R73	TumorDesc TumorDetails:T10 Desc:T403	
R74	TumorDesc TumorDetails:T404 Desc:T403	
R75	BeginsOnOrAt Arg1:T405 Arg2:T406	
T437	ClinicalCondition 153 178	pancreatic adenocarcinoma
A173	TreatmentIntentVal T437 others
T438	Metastasis 142 152	metastatic
A174	EpisodeDescription T438 Progression
T439	Histology 164 178	adenocarcinoma
T440	Histology 421 435	adenocarcinoma
T441	RadPathResult 545 549	mass
A175	RadPathResultVal T441 InitialCancerDiagnosis
T442	Site 529 544	pancreatic head
R76	SiteOf Arg1:T442 Arg2:T441	
R77	ResultOfTest Desc:T441 Test:T307	
T443	Site 720 727	biliary
T444	Site 797 804	biliary
R78	SiteOf Arg1:T443 Arg2:T312	
R79	SiteOf Arg1:T444 Arg2:T311	
T445	Pathology 1083 1092	Pathology
A176	IntentVal T445 diagnosis
R80	HappensAtOnDuring Arg1:T325 Arg2:T445	
R81	TestOrProcedureReveals Test:T445 Desc:T326	
R82	TestOrProcedureReveals Test:T445 Desc:T327	
R83	TestOrProcedureReveals Test:T445 Desc:T329	
R84	TestOrProcedureReveals Test:T445 Desc:T328	
R85	TestOrProcedureReveals Test:T445 Desc:T330	
R86	TestOrProcedureReveals Test:T445 Desc:T331	
R87	TestOrProcedureReveals Test:T445 Desc:T332	
T446	DiseaseState 1359 1368	recurrent
A177	NegationModalityVal T446 uncertain_in_present
A179	NegationModalityVal T338 uncertain_in_present
R88	ResultOfTest Desc:T446 Test:T336	
T447	MedicationName 2546 2566	long-acting morphine
A180	TreatmentContinuityVal T447 continuing
A181	TreatmentTypeVal T447 others
A182	TreatmentIntentVal T447 others
A183	TreatmentCategory T447 Supportive
R89	TreatmentAdministeredForProblem Treatment:T447 Prob:T372	
T448	Symptom 2691 2697	weight
A184	IsPresentOnFirstCancerDiagnosis T448 no
A185	IsCausedByDiagnosedCancer T448 unclear
A186	ChronicVal T448 non-chronic
A187	ContinuityVal T448 improving
T449	PhysicalActivity 2848 2859	very active
A188	IsStoppedOrContinuing T449 continuing
T450	PerformanceStatus 2869 2881	ECOG PS of 0
T451	Employment 3949 3956	Retired
A189	IsStoppedOrContinuing T451 stopped
T452	LivingCondition 3915 3941	Two adult children live in
A190	ExperiencerVal T452 family
R90	HappensBefore Arg1:T408 Arg2:T410	
T453	Symptom 2783 2826	Bowel movements are regular and well-formed
A191	NegationModalityVal T453 negated
T454	ProcedureName 13089 13095	biopsy
A192	IntentVal T454 diagnosis
R91	TestOrProcedureReveals Test:T454 Desc:T416	
R92	HappensAtOnDuring Arg1:T454 Arg2:T417	
T455	TreatmentType 13497 13513	systemic therapy
A193	NegationModalityVal T455 hypothetical_in_future
A194	TreatmentTypeVal T455 maintenance
A195	TreatmentIntentVal T455 palliative
T456	DiseaseState 13563 13572	remission
A196	EpisodeDescription T456 Others
A197	NegationModalityVal T456 hypothetical_in_future
T457	DiseaseState 14247 14263	residual disease
T458	DiseaseState 14526 14544	disease progresses
A198	NegationModalityVal T458 hypothetical_in_future
A199	NegationModalityVal T457 uncertain_in_present
T459	DiseaseState 14353 14364	recurrences
A200	NegationModalityVal T459 hypothetical_in_future
R93	TreatmentAdministeredForProblem Treatment:T423 Prob:T459	
R94	TreatmentAdministeredForProblem Treatment:T424 Prob:T458	
A202	NegationModalityVal T431 uncertain_in_present
A203	DiseaseStateVal T458 progression-others
A204	DiseaseStateVal T459 progression-recurrence
A205	DiseaseStateVal T457 progression-recurrence
A206	DiseaseStateVal T456 remission
T461	DiseaseState 132 141	recurrent
A207	DiseaseStateVal T461 progression-recurrence
R96	SizeOf Arg1:T316 Arg2:T441	
R97	SizeOf Arg1:T327 Arg2:T328	
A208	DiseaseStateVal T446 progression-recurrence
T462	Datetime 1948 1956	09/12/20
R98	HappensAtOnDuring Arg1:T355 Arg2:T462	
R63	Temporal Arg1:T361 Arg2:T366	
A178	PerformanceStatusType T450 ECOG
A172	DiseaseStateVal T10 progression-recurrence
A209	NegationModalityVal T422 planned_in_future
R99	TreatmentAdministeredForProblem Treatment:T423 Prob:T457	
R95	InclusionCriteriaFor Arg1:T459 Arg2:T426	
R100	InclusionCriteriaFor Arg1:T459 Arg2:T428	
R101	InclusionCriteriaFor Arg1:T459 Arg2:T427	
R102	InclusionCriteriaFor Arg1:T459 Arg2:T429	
T460	hpi_start 0 2	Ms
T463	hpi_end 2880 2882	0.
T464	ap_start 12649 12659	Impression
T465	ap_end 15737 15748	identified.
R103	HappensAfter Arg1:T417 Arg2:T419	
